robert f kennedy jr glp 1 RFK Jr. says China is 'eating our lunch' in biotech advances RFK Jr. promotes peptides. Now

Cases of cyclosporiasis, a pathogen often caused by contaminated produce, are rising across several U.S

For insureds across the life sciences ecosystem, a proactive approach to compliance, documentation, and transparent communication is essential

Learn about their experience.

Two leading glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and type 2 diabetes Novo Nordisk A/Ss semaglutide (Wegovy/Ozempic) and Eli Lilly and Co.s tirzepatide (Mounjaro/Zepbound) are advancing in China after taking the U.S

G49, a dual glucagon/glucagon-like peptide-1 receptor agonist, triggers an inter-organ crosstalk between adipose tissue, pancreas and liver, leading to brown fat activation with the final outcomes of increased energy expenditure and body weight loss.

This innovative oral GLP-1 is a small molecule medication that, unlike the Wegovy pill, doesnt require that you take it on an empty stomach.